Observational Study of Asciminib Tolerability, Safety, Effectiveness for Ph+ CML-CP in Germany (NCT07549516)
ClinicalTrials.gov Studies
Summary
NIH registered observational study NCT07549516 on ClinicalTrials.gov to assess real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients in Germany. The study enrols patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI). No compliance obligations or regulatory actions are associated with this registry entry.
“The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This entry registers a new observational study on ClinicalTrials.gov evaluating asciminib tolerability, safety, and real-world effectiveness in Ph+ CML-CP patients in Germany. The study includes both newly diagnosed patients and those previously treated with one ATP-competitive tyrosine kinase inhibitor. This is a registry entry for an observational study, not a regulatory action or clinical guideline.
Healthcare providers and clinical investigators involved in CML treatment may reference this registry for awareness of ongoing real-world evidence generation for asciminib in Germany. Pharmaceutical companies developing or marketing asciminib may monitor study outcomes for post-marketing evidence. No immediate compliance obligations arise from this registration.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Observational NCT07549516 Kind: OBSERVATIONAL Apr 24, 2026
Abstract
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Conditions: Leukemia, Chronic Myeloid
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.